Zydus Lifesciences to scale up US specialties business
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
The company is also looking at an inorganic opportunity over the next two years to have a commercially ready footprint in the US
Collaboration with KNAUER to streamline and improve the scale-up of LNP formulations
The partnership marks a significant milestone in integrating digital health education into medical curricula
Gross profit was Rs. 328.8 crore, up by 27.8% YoY with a gross margin expansion of 418 bps to 55.7%
This project is supported by the Irish Government through IDA Ireland
Revenue up 16.3% to Rs 5,600 crore versus Rs 4,814 crore
For the 2024 outlook, sales growth is now expected to be 22-28% at CER
Our centers are performing as expected or even better
The company reported total income at Rs. 509.8 crore in Q1 FY25 as compared to Rs. 570.3 crore in Q1 FY24
Subscribe To Our Newsletter & Stay Updated